Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Payables: 2020-2024

Historic Payables for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $8.0 million.

  • Mereo BioPharma Group's Payables fell 87.96% to $879,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 46.98%. This contributed to the annual value of $8.0 million for FY2024, which is 239.94% up from last year.
  • As of FY2024, Mereo BioPharma Group's Payables stood at $8.0 million, which was up 239.94% from $2.3 million recorded in FY2023.
  • Mereo BioPharma Group's Payables' 5-year high stood at $16.8 million during FY2022, with a 5-year trough of $2.3 million in FY2023.
  • Moreover, its 3-year median value for Payables was $8.0 million (2024), whereas its average is $9.0 million.
  • In the last 5 years, Mereo BioPharma Group's Payables surged by 399.25% in 2022 and then tumbled by 86.05% in 2023.
  • Over the past 5 years, Mereo BioPharma Group's Payables (Yearly) stood at $4.3 million in 2020, then declined by 21.29% to $3.4 million in 2021, then soared by 399.25% to $16.8 million in 2022, then plummeted by 86.05% to $2.3 million in 2023, then skyrocketed by 239.94% to $8.0 million in 2024.